China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, Hunan Xiangzhong Pharmaceutical, received approval from the Chinese drug administration to produce and market levetiracetam oral solution, according to a Shanghai Stock Exchange disclosure on Tuesday.

The National Medical Products Administration handed down a drug registration certificate to the pharmaceutical company.

The drug is an adjunctive treatment for partial seizures in adults, children and infants over one month of age with epilepsy, the disclosure said.

The company's shares rose 1% in recent trade.